OIPE
NOV 15 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Total Number of Pages in This Submission: 7 + **	Attorney Docket Number: P0026US20

ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) ____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) *(please identify below)*:

**** Copies of 38 references; Return postcard**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Hugh Wang, Reg. No. 47,163
Signature	
Date	November 13, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: US Patent and Trademark Office, PO Box 2327, Arlington VA 22202 on this date: November 13, 2002

Typed or printed name	Hugh Wang		
Signature		Date	November 13, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: US Patent and Trademark Office, PO Box 2327, Arlington VA 22202 on this date November 13, 2002

By: _____
Hugh Wang

OIPE
NOV 15 2002
PATENT & TRADEMARK OFFICE

PATENT
Attorney Docket No.: P0026US20

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John Welsh et al.

Application No.: 10/054,498

Filed: January 22, 2002

For: Genes Overexpressed In Prostate Disorders As Diagnostic And Therapeutic Targets

Examiner: Hayshemi

Art Unit: 1642

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" section on any patents to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement, and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No.

50-1885. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Hugh Wang
Reg. No. 47,163

Genomics Institute of the Novartis Research Foundation
10675 John Jay Hopkins Drive
San Diego, CA 92121
Tel: (858) 812-1500
Fax: (858) 812-1981

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC
NOV 15 2002
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

TECH CENTER 1600/2900
RECEIVED
NOV 18 2002

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number: Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AA	WO 01/34802 A2	May 17, 2001	Corxia Corp.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AB	BOOTCOV et al., Proc. Natl. Acad. Sci. USA, Vol. 94, No. 21, pp. 11514-11519 (1997); MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF- superfamily.	
	AC	BRAWER, Semin. Surg. Oncol. 18: 3-9, 2000; Prostate-specific antigen.	
	AD	BRAWER et al., Am. J. Clin. Pathol. 92: 760-764, 1989; Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy.	
	AE	BUSSEMAKERS et al., Cancer Res., Vol. 59, pp. 5975-5979 (1999); DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.	
	AF	CATALONA et al., JAMA 270:948-954, 1993; Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.	
	AG	CHANG et al., Cancer Res., Vol. 57, pp. 4075-4081 (1997); Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002
PATENT & TRADEMARK OFFICE

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AH	CHOO et al., Prostate, Vol. 40, pp. 150-158 (1999); Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames.	
	AI	DHANASEKARAN et al., Nature 412: 822-826 (2001); Delineation of prognostic biomarkers in prostate cancer.	
	AJ	EMMERT-BUCK et al., Am. J. Pathol., Vol. 156, pp. 1109-1115 (2000); Molecular Profiling of Clinical Tissue Specimens: Feasibility and Applications	
	AK	FERDINANDUSSE et al., J Lipid Res 2000 Nov;41(11):1890-6; Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.	
	AL	HOANG et al., Am. J. Pathol., Vol. 156, pp. 857-864 (2000); A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.	
	AM	HROMOS et al., Biochim. Biophys. Acta. Vol. 1354, No. 1, pp. 40-44 (1997); PLAB, a novel placental bone morphogenetic protein.	
	AN	HUANG et al., Genomics, Vol. 59, pp. 178-186 (1999); Prostate Cancer Expression Profiling by cDNA Sequencing Analysis.	
	AO	JIANG et al., Am. J. Surg. Pathol. 25: 1397-1404, 2001; P504S: a new molecular marker for the detection of prostate carcinoma.	
	AP	KANNAN et al., FEBS Lett., Vol. 470, No. 1, pp. 77-82 (2000); Profile of gene expression regulated by induced p53: connection to the TGF- family.	
	AQ	KAZAMA, J. Biol. Chem., Vol. 270, pp. 66-72 (1995); Hepsin, a Putative Membrane-associated Serine Protease, Activates Human Factor VII and Initiates a Pathway of Blood Coagulation on the Cell Surface Leading to Thrombin Formation.	
	AR	KUHAJDA, in Nutrition, Vol. 16, No. 3, pp. 202-208 (2000); Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.	
	AS	LALANI et al., Cancer Metastasis Rev., Vol. 16, pp. 29-66 (1997); Molecular and cellular biology of prostate cancer.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002
PATENT & TRADEMARK OFFICE

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AT	LI et al., Science, Vol. 275, pp. 1943-1947 (1997); PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer	
	AU	LUO et al., Cancer Res. 61: 4683-88, 2001; Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.	
	AV	MAGEE et al., Cancer Res. 61: 5692-96, 2001; Expression profiling reveals hepsin overexpression in prostate cancer.	
	AW	MARCELLI et al., Cancer Res., Vol. 60, pp. 944-949 (2000); Androgen receptor mutations in prostate cancer.	
	AX	MIKI et al., PNAS 98: 2199-2204, 2001; Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays.	
	AY	NAM et al., J. Clin. Oncol. 18: 1036-1042, 2000; Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.	
	AZ	PILARSKY et al., Prostate, Vol. 36, pp. 85-91 (1998); Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer.	
	BA	PIZER et al., Prostate 2001 May 1;47(2):102-10; Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.	
	BB	SUN et al., Cancer Res., Vol. 57, pp. 18-23 (1997); Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples.	
	BC	SCHER et al., Urology 55: 323-327, 2000; Clinical states in prostate cancer: toward a dynamic model of disease progression.	
	BD	SAFFRAN et al., Cancer Metastasis Rev. 18: 437-449 (1999); Target antigens for prostate cancer immunotherapy.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002
PATENT AND TRADEMARK OFFICE
JC37

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/054,498
Filing Date	January 22, 2002
First Named Inventor	John Welsh
Group Art Unit	1642
Examiner Name	Hayshemi
Attorney Docket Number	P0026US20

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BE	STAMEY et al., J. Urol. 166: 2171-77, 2001; Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.	
	BF	TANIMOTO et al., Cancer Res., Vol. 57, pp. 2884-2887 (1997); Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.	
	BG	TORRES-ROSADO et al., Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 7181-7185 (1993); Hepsin, a Putative Cell-Surface Serine Protease, is Required for Mammalian Cell Growth.	
	BH	TSUJI et al., J. Biol. Chem., Vol. 266, pp. 16948-16953 (1991); Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization.	
	BI	VOELLER et al., Cancer Res., Vol. 58, pp. 2520-2523 (1998); Beta-catenin mutations in human prostate cancer.	
	BJ	VU et al., J. Biol. Chem., Vol. 272, pp. 31315-31320 (1997); Identification and Cloning of the Membrane-associated Serine Protease, Hepsin, from Mouse Preimplantation Embryos.	
	BK	WU et al., J. Clin. Invest., Vol. 101, pp. 321-326 (1998); Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.	
	BL	YANG et al., Cancer Res., Vol. 58, pp. 3732-3735 (1998); Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.